Pain, Burning Completed Phase 2 Trials for Fulranumab (DB12102)

IndicationStatusPhase
DBCOND0044609 (Pain, Burning)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00929188A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related PainTreatment